Pharmaceutical Manufacturing Plant for Sale in Haridwar — WHO-GMP, Running & Scalable
A running, WHO-GMP certified and Schedule M-compliant oral solid dosage (OSD) manufacturing plant producing tablets, capsules, liquid orals and ointments — with a 600+ product-approval portfolio (including a licensed psychotropic range), ₹2.5 crore of monthly production and clear headroom to ₹50+ crore annual turnover. A serious strategic acquisition, offered to qualified buyers only.
*Monthly production, run-rate and scale potential are as represented by the seller and subject to independent due-diligence verification. Figures are indicative and do not constitute an offer, a valuation, or financial advice.
A WHO-GMP platform that already produces — and has room to double
This pharmaceutical manufacturing plant for sale in Haridwar, Uttarakhand, is a running, WHO-GMP certified and Schedule M-compliant oral solid dosage facility offered at an expected price of ₹30 crore. It manufactures tablets, capsules, syrups / liquid orals and ointments / topicals under one roof, carries a documented portfolio of 600+ product approvals — including a licensed psychotropic range — and is currently producing at about ₹2.5 crore per month with all key statutory and regulatory approvals in place. This page sets out what is on offer, what it produces, where the scale sits, and what to verify before you sign — written for real diligence, not a brochure.
For a strategic buyer, pharma group or investor, the logic is direct: you acquire a certified, multi-dosage platform that is already generating revenue and holds a deep approval book, rather than spending 18–24 months building and certifying a greenfield site while competitors capture demand. This is a pharma business for sale in India whose value rests on three things at once — current cash generation, a hard-to-replicate 600+ approval portfolio, and installed capacity that scales the plant toward ₹50+ crore of annual turnover.
- Location
- Haridwar, Uttarakhand — an established, incentive-era pharma manufacturing belt in the Haridwar–Roorkee corridor, within a day’s road reach of Delhi-NCR and Dehradun.
- Facility type
- Oral solid dosage (OSD) plus topical — tablets, capsules, liquid orals and ointments under one WHO-GMP licence.
- Compliance
- WHO-GMP certified · Schedule M compliant, with all key statutory and regulatory approvals represented as in place.
- Product portfolio
- 600+ approved formulations across four dosage forms, including a licensed psychotropic range — full schedule available under NDA.
- Current output
- ₹2.5 crore per month (~₹30 crore annualised), with installed capacity scalable to ₹50+ crore per year (seller-represented).
- Team
- A competent and experienced team across production, QA/QC, stores and administration is in place.
- Property
- Freehold — ~71,278 sq ft land, ~37,674 sq ft built-up, with complete machinery and equipment included.
- Headroom
- Installed capacity materially exceeds current output — the clearest growth lever in the deal.
Why Haridwar
Haridwar is one of North India’s most established pharmaceutical manufacturing clusters, built up during the state’s excise-incentive era alongside neighbouring Roorkee. For a buyer, the value isn’t the address — it’s the operating ecosystem you inherit on day one:
- Established cluster
- Excipient and packaging suppliers, contract testing labs and pharma-equipment engineers operate locally — keeping lead times and machine downtime short.
- Trained talent pool
- A mature Uttarakhand pharma workforce means GMP-literate operators, QA/QC analysts and documentation staff are available without a long hire-and-train runway.
- Connectivity
- Road and rail links to Delhi-NCR, Dehradun and the wider North Indian market support both raw-material inflow and pan-India dispatch of finished goods.
- Regulatory familiarity
- Uttarakhand state drug authorities and local consultants handle CDSCO, Schedule M and WHO-GMP processes routinely, smoothing licence variations and renewals.
- Legacy base
- The region built its scale in the incentive era; the supplier density and infrastructure remain, even though the original tax holiday has ended.
The physical asset & what its certifications unlock
The ~37,674 sq ft built-up block on ~71,278 sq ft of freehold land is laid out for compliant oral-solid, liquid and semi-solid manufacturing — segregated production, warehousing and quality-control areas built around GMP material and personnel flow. As a brownfield, operating asset, you take on a facility with a known construction and utility history rather than greenfield unknowns. Complete machinery and equipment are included; a full asset and utility schedule is provided with the due-diligence pack and should be independently audited.
| Certification / approval | What it enables | Market access |
|---|---|---|
| WHO-GMP | Recognised WHO Good Manufacturing Practice standard | Base credential for RoW / semi-regulated export and tender business (per-market product registration still applies) |
| Revised Schedule M | Compliance with India’s upgraded GMP norms (in force 2025) | De-risks the unit against ongoing CDSCO risk-based inspections |
| Psychotropic / NDPS range | Licensed manufacture of controlled psychotropic formulations | A high-barrier, differentiated segment few units are approved for |
| Product approvals (CDSCO) | Product-level regulatory recognition | Legal manufacture of the 600+ approved formulation list |
A validated, self-sufficient utility backbone
The plant carries the full utility set expected of a WHO-GMP OSD facility — the systems that determine how much of the installed capacity can actually be run:
- Quality laboratories
- Dedicated QC laboratory and QA laboratory for in-house release testing, method control and documentation.
- Water systems
- RO system and purified water (PW) generation and loop supporting compliant product and cleaning requirements.
- Air handling
- Validated HVAC across classified manufacturing areas — central to cleanroom classification and cross-contamination control.
- Power continuity
- DG sets and UPS for backup power and uninterrupted operation of critical equipment.
- Effluent & environment
- ETP / STP systems for effluent and sewage treatment, supporting environmental consents.
- Plant & machinery
- Complete machinery and equipment across all four dosage-form sections, included in the sale.
Four dosage-form sections under one WHO-GMP roof
The plant runs four installed manufacturing sections, giving a single buyer the flexibility to re-mix output across solids, liquids and semi-solids as demand shifts — both a diversification and a client-retention advantage:
| Section | Dosage forms | Typical applications |
|---|---|---|
| Tablets | Uncoated, film-coated & sustained-release tablets | The high-volume core of the domestic OSD market |
| Capsules | Hard-gelatin capsules (and softgel scope) | Antibiotics, gastro, nutraceutical and CNS ranges |
| Liquid orals | Syrups & suspensions | Paediatric, cough-cold, haematinic and antacid lines |
| Ointments / topicals | Ointments, creams & gels | Dermatological and anti-infective external preparations |
A ready-to-sell range of 600+ approved formulations
The plant carries a documented portfolio of 600+ approved product formulations — a genuine value driver, since each approval carries the time, cost and paperwork a new manufacturer would otherwise have to build from scratch. The range spans all four dosage forms and includes a licensed psychotropic / CNS range that few competing units are approved to make:
| Therapeutic area | Representative scope across the portfolio |
|---|---|
| Analgesics & anti-inflammatories | NSAID and combination pain-management ranges across tablets, capsules and liquids |
| Antibiotics & antimicrobials | Anti-infective and antifungal ranges across solids and topicals |
| Gastro & PPIs | Acid-control and pro-kinetic formulations |
| CNS / psychotropic (licensed) | Controlled psychotropic range — a high-barrier, differentiated segment |
| Dermatologicals & nutraceuticals | Topical preparations plus haematinic, calcium and multivitamin lines |
Therapeutic areas above are indicative of portfolio scope; the full molecule-level approval schedule is shared with qualified buyers under NDA. Segment breadth makes the portfolio well-suited to third-party manufacturing, PCD supply and — on the existing WHO-GMP base — export registration.
One licensed platform, several ways to earn
A WHO-GMP, multi-dosage plant with a 600+ approval book supports several revenue modes at once — the flexibility that underpins much of India’s oral-solids sector. A buyer can run any combination of them from day one:
Continue and grow the existing production base; take on third-party / contract manufacturing and loan-licence work to fill installed capacity; supply a PCD / franchise network under the approved range; and, for an operating pharma company, in-house its own brand production to reclaim margin currently paid to outside manufacturers. The multi-dosage licence lets you re-mix output as client demand shifts — diversification and client-retention insurance in one asset.
The numbers — read honestly
The figures below are as represented by the seller and must be validated in diligence against audited accounts and GST filings. The headline is a genuine operating business: current production of about ₹2.5 crore per month annualises to roughly ₹30 crore — but note the correction that matters most: a revenue run-rate is not a profit figure. No margin has been represented here, so the operating (EBITDA) profitability must be confirmed from the audited accounts before any earnings-based valuation.
| Metric | As represented | Note for buyer |
|---|---|---|
| Monthly production | ₹2.50 Cr | Reconcile to GST returns + bank statements |
| Annual run-rate | ~₹30 Cr | Annualised from monthly output; verify against audited accounts |
| Scale potential | ₹50+ Cr | At higher utilisation — validate against capacity & utilities |
| Operating margin / EBITDA | Not represented | Confirm from audited P&L — do not assume |
| Approved formulations | 600+ | Core intangible value — verify against licence |
| Psychotropic range | Included | Confirm NDPS / psychotropic licence transfer |
| Property | Freehold | Verify title; ~71,278 sq ft land / ~37,674 sq ft built-up |
Expected price — and how to read it
The expected price is ₹30 crore, negotiable subject to due diligence. Unlike a thin asset-only listing, this asset generates meaningful revenue today, so the number sits at roughly 1× the current annualised run-rate — but a revenue multiple is not a valuation on its own:
How to value it: commission an independent valuation of (1) land + building at prevailing Haridwar industrial rates, (2) plant & machinery at fair market value, and (3) intangibles — the 600+ approvals, the WHO-GMP and psychotropic licences, and client relationships — then cross-check against the earnings multiple once audited EBITDA is known. For a wider view of build-versus-buy economics, our pharma plant setup cost calculator shows what an equivalent greenfield facility would cost to create from scratch.
Investment calculator
Because no margin has been represented, this calculator lets you set your own gross-margin assumption, deduct your own operating cost to reach EBITDA, and test a scale-up scenario. Unlevered (all-equity) — layer in your own debt separately. Every figure is illustrative until confirmed in diligence.
Illustrative only. Excludes working-capital movements, tax, and capex beyond the operating cost you set. Not financial advice — verify all inputs in due diligence.
Why now
Most plants that come to market are either distressed or non-compliant retrofits. This one is WHO-GMP certified, Schedule M-compliant and already producing ₹2.5 crore a month — you skip both the 18–24 month greenfield build and the compliance-upgrade risk, and start from an operating base.
A licensed psychotropic / CNS range is a high-barrier segment — the NDPS and psychotropic approvals are slow and difficult to obtain, so few competitors hold them. Inherited (subject to licence transfer), this is a differentiated, higher-value line that a new entrant simply cannot replicate quickly.
The gap between current ₹30 crore run-rate output and the ₹50+ crore installed potential is the clearest lever any buyer has: filling existing lines and improving product mix drives revenue and margin with limited incremental capex. On top of that, the existing WHO-GMP status shortens the path to export registration.
What works in your favour
What you’re taking on
| Risk | Impact | Mitigation |
|---|---|---|
| Margin not represented | Price justification depends on unverified EBITDA | Gate the deal on audited P&L; value on asset + approval base if earnings fall short |
| Psychotropic licence transfer | NDPS approvals may not transfer automatically | Confirm re-endorsement / re-grant route with authorities pre-close |
| Capacity under-utilisation | Return stays modest if lines aren’t filled | Named client-acquisition plan; loan-licence deals; export/PCD expansion |
| Installed vs actual capacity | Overstated throughput inflates the ₹50 Cr upside | Validate against batch records & utility capacity pre-close |
| WHO-GMP renewal & scope | Certification validity and product scope must be current | Check certificate validity, inspection history & open observations |
| Client concentration / churn | Revenue shock if key accounts exit | Top-client contribution check; transition & retention agreements |
None of these is fatal with active management — but this is an operating business bought on its platform value and confirmed earnings, not a passive holding.
Who this is right for
- Established pharma company
- Wanting certified, multi-dosage capacity plus a 600+ product range — including a psychotropic line — to in-house production without the greenfield wait.
- Marketing / PCD / distribution firm
- Ready to secure its own supply, own the manufacturing margin, and sell an established portfolio under its own PCD brand.
- Investor / group with operations capability
- Able to fill installed capacity toward ₹50+ crore and extend the existing WHO-GMP base into export markets.
- Not a fit if
- You want passive income, have no route to operating expertise, or expect to acquire the psychotropic capability without completing the statutory licence-transfer process — the value is in what you operate and build on the platform.
Next steps for serious buyers
Detailed information — including plant identity, exact address, licence numbers and financials — is shared only after an initial discussion and, where appropriate, a signed NDA, with serious and qualified buyers only. A site visit is essential; a facility of this type cannot be assessed from documents alone. When you make contact, the diligence pack covers:
- Financials
- Audited accounts (last 3 years), reconciled to GST filings — with a clear split of gross margin vs EBITDA.
- Certifications & licences
- WHO-GMP certificate, CDSCO manufacturing licence (scope + validity) and Schedule M compliance status.
- Psychotropic / NDPS approvals
- The controlled-substance licences and the transfer / re-endorsement route on a change of control.
- Product approvals
- Full 600+ formulation / approval schedule, checked against the licence.
- Plant & machinery
- Equipment schedule with age, condition and maintenance history across all four sections.
- Capacity & utilities
- Throughput validation backed by batch records; HVAC, PW, DG/UPS and ETP/STP capacity.
- Property & legal
- Freehold title / tenure documents, environmental consents, and a change-of-control review of key contracts.
Request the due-diligence pack & arrange a site visit
WHO-GMP & CDSCO licence scope, psychotropic-licence position, 600+ product-approval schedule, machinery list, three-year financials and a transition timeline — shared with qualified, funding-ready buyers under NDA. Handled in strict confidence.
Serious, funding-ready buyers only · Detailed information after initial discussion / NDA · Site visits by appointment
Frequently asked questions
What certifications does the plant hold?
What is the expected price?
How much is the plant currently producing?
What can the plant manufacture?
How many products are approved?
Does the psychotropic licence transfer with the plant?
Can the plant export?
Who is this opportunity suitable for?
Figures on this page relating to production, run-rate, scale potential, approvals, area and certifications are indicative, are as represented by the seller where noted, and are subject to independent verification. Land tenure, WHO-GMP and Schedule M status, product approvals and psychotropic / NDPS licences must be confirmed by title search and regulatory checks, including the transfer route on a change of control. Nothing here constitutes an offer, a valuation, or investment / financial advice.
